{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:31:26Z","timestamp":1790303486254,"version":"4.1.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40266-019-00685-6","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T05:11:12Z","timestamp":1560489072000},"page":"719-731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Use of Cholinesterase Inhibitors in Non-Alzheimer\u2019s Dementias"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3596-8612","authenticated-orcid":false,"given":"Paul","family":"Noufi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-6816","authenticated-orcid":false,"given":"Rita","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3880-0631","authenticated-orcid":false,"given":"Sajeeka","family":"Jeyakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1493-3931","authenticated-orcid":false,"given":"George T.","family":"Grossberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,14]]},"reference":[{"key":"685_CR1","unstructured":"World Health Organization WHO. Dementia. 2017. \n                    https:\/\/www-who-int.ezp.slu.edu\/en\/news-room\/fact-sheets\/detail\/dementia\n                    \n                  . Accessed 03 Sep 2019."},{"key":"685_CR2","unstructured":"DSM-5 A. Neurocognitive Disorders. Diagnostic and Statistical Manual of Mental Disorders. DSM Library: American Psychiatric Association; 2013."},{"key":"685_CR3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.trci.2018.04.008","volume":"4","author":"J Cummings","year":"2018","unstructured":"Cummings J, Reiber C, Kumar P. The price of progress: funding and financing Alzheimer\u2019s disease drug development. Alzheimer\u2019s Dement (New York, N Y). 2018;4:330\u201343. \n                    https:\/\/doi.org\/10.1016\/j.trci.2018.04.008\n                    \n                  .","journal-title":"Alzheimer\u2019s Dement (New York, N Y)."},{"issue":"11","key":"685_CR4","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40266-017-0499-x","volume":"34","author":"R Khoury","year":"2017","unstructured":"Khoury R, Patel K, Gold J, Hinds S, Grossberg GT. Recent Progress in the Pharmacotherapy of Alzheimer\u2019s Disease. Drugs Aging. 2017;34(11):811\u201320. \n                    https:\/\/doi.org\/10.1007\/s40266-017-0499-x\n                    \n                  .","journal-title":"Drugs Aging"},{"issue":"2","key":"685_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","volume":"66","author":"PT Francis","year":"1999","unstructured":"Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer\u2019s disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66(2):137. \n                    https:\/\/doi.org\/10.1136\/jnnp.66.2.137\n                    \n                  .","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"685_CR6","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2165\/00003088-200241100-00003","volume":"41","author":"MW Jann","year":"2002","unstructured":"Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002;41(10):719\u201339. \n                    https:\/\/doi.org\/10.2165\/00003088-200241100-00003\n                    \n                  .","journal-title":"Clin Pharmacokinet"},{"key":"685_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd005593","author":"J Birks","year":"2006","unstructured":"Birks J. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Of Syst Rev. 2006. \n                    https:\/\/doi.org\/10.1002\/14651858.cd005593\n                    \n                  .","journal-title":"Cochrane Database Of Syst Rev."},{"key":"685_CR8","doi-asserted-by":"publisher","unstructured":"Nordberg A, Ballard C, Bullock R, Darreh-Shori T, Somogyi M. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer\u2019s disease. The primary care companion for CNS disorders. 2013;15(2). \n                    https:\/\/doi.org\/10.4088\/pcc.12r01412\n                    \n                  .","DOI":"10.4088\/pcc.12r01412"},{"issue":"6 Suppl","key":"685_CR9","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1097\/01.jam.0000095367.55043.b5","volume":"4","author":"AR Gustavson","year":"2003","unstructured":"Gustavson AR, Cummings JL. Cholinesterase inhibitors in non-Alzheimer dementias. J Am Med Dir Assoc. 2003;4(6 Suppl):S165\u20139. \n                    https:\/\/doi.org\/10.1097\/01.jam.0000095367.55043.b5\n                    \n                  .","journal-title":"J Am Med Dir Assoc"},{"issue":"6","key":"685_CR10","first-page":"775","volume":"3","author":"JL Reingold","year":"2007","unstructured":"Reingold JL, Morgan JC, Sethi KD. Rivastigmine for the treatment of dementia associated with Parkinson\u2019s disease. Neuropsychiatr Dis Treat. 2007;3(6):775\u201383.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"2","key":"685_CR11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.bbr.2009.12.044","volume":"221","author":"A Contestabile","year":"2011","unstructured":"Contestabile A. The history of the cholinergic hypothesis. Behav Brain Res. 2011;221(2):334\u201340. \n                    https:\/\/doi.org\/10.1016\/j.bbr.2009.12.044\n                    \n                  .","journal-title":"Behav Brain Res"},{"key":"685_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.brainres.2017.06.023","volume":"1670","author":"G Pepeu","year":"2017","unstructured":"Pepeu G, Grazia Giovannini M. The fate of the brain cholinergic neurons in neurodegenerative diseases. Brain Res. 2017;1670:173\u201384. \n                    https:\/\/doi.org\/10.1016\/j.brainres.2017.06.023\n                    \n                  .","journal-title":"Brain Res"},{"issue":"1","key":"685_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","volume":"14","author":"TF Outeiro","year":"2019","unstructured":"Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, et al. Dementia with Lewy bodies: an update and outlook. Mol Neurodegener. 2019;14(1):5. \n                    https:\/\/doi.org\/10.1186\/s13024-019-0306-8\n                    \n                  .","journal-title":"Mol Neurodegener."},{"issue":"1","key":"685_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88\u2013100. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000004058\n                    \n                  .","journal-title":"Neurology."},{"issue":"3","key":"685_CR15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41380-018-0130-5","volume":"24","author":"S Nejad-Davarani","year":"2019","unstructured":"Nejad-Davarani S, Koeppe RA, Albin RL, Frey KA, M\u00fcller MLTM, Bohnen NI. Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [(18)F]-FEOBV. Mol Psychiatry. 2019;24(3):322\u20137. \n                    https:\/\/doi.org\/10.1038\/s41380-018-0130-5\n                    \n                  .","journal-title":"Mol Psychiatry"},{"issue":"2","key":"685_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1365-2990.2011.01203.x","volume":"38","author":"BN Dugger","year":"2012","unstructured":"Dugger BN, Murray ME, Boeve BF, Parisi JE, Benarroch EE, Ferman TJ, et al. Neuropathological analysis of brainstem cholinergic and catecholaminergic nuclei in relation to rapid eye movement (REM) sleep behaviour disorder. Neuropathol Appl Neurobiol. 2012;38(2):142\u201352. \n                    https:\/\/doi.org\/10.1111\/j.1365-2990.2011.01203.x\n                    \n                  .","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"4","key":"685_CR17","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/j.1471-4159.1990.tb03162.x","volume":"55","author":"EK Perry","year":"1990","unstructured":"Perry EK, Marshall E, Kerwin J, Smith CJ, Jabeen S, Cheng AV, et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem. 1990;55(4):1454\u20136.","journal-title":"J Neurochem"},{"issue":"3","key":"685_CR18","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.ncl.2007.03.001","volume":"25","author":"TJ Ferman","year":"2007","unstructured":"Ferman TJ, Boeve BF. Dementia with Lewy bodies. Neurol Clin. 2007;25(3):741\u20137. \n                    https:\/\/doi.org\/10.1016\/j.ncl.2007.03.001\n                    \n                  .","journal-title":"Neurol Clin"},{"issue":"3","key":"685_CR19","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.neuroimage.2008.01.010","volume":"40","author":"JT O\u2019Brien","year":"2008","unstructured":"O\u2019Brien JT, Colloby SJ, Pakrasi S, Perry EK, Pimlott SL, Wyper DJ, et al. Nicotinic alpha4beta2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations. NeuroImage. 2008;40(3):1056\u201363. \n                    https:\/\/doi.org\/10.1016\/j.neuroimage.2008.01.010\n                    \n                  .","journal-title":"NeuroImage."},{"issue":"4","key":"685_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","volume":"13","author":"D Aarsland","year":"2017","unstructured":"Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13(4):217\u201331. \n                    https:\/\/doi.org\/10.1038\/nrneurol.2017.27\n                    \n                  .","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"685_CR21","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1007\/s00259-016-3349-x","volume":"43","author":"R Roy","year":"2016","unstructured":"Roy R, Niccolini F, Pagano G, Politis M. Cholinergic imaging in dementia spectrum disorders. Eur J Nucl Med Mol Imaging. 2016;43(7):1376\u201386. \n                    https:\/\/doi.org\/10.1007\/s00259-016-3349-x\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"685_CR22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.neulet.2012.02.083","volume":"514","author":"V Kotagal","year":"2012","unstructured":"Kotagal V, Muller ML, Kaufer DI, Koeppe RA, Bohnen NI. Thalamic cholinergic innervation is spared in Alzheimer disease compared to parkinsonian disorders. Neurosci Lett. 2012;514(2):169\u201372. \n                    https:\/\/doi.org\/10.1016\/j.neulet.2012.02.083\n                    \n                  .","journal-title":"Neurosci Lett"},{"issue":"2","key":"685_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/jnnp.65.2.155","volume":"65","author":"M Asahina","year":"1998","unstructured":"Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson\u2019s disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry. 1998;65(2):155\u201363.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"685_CR24","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1212\/01.wnl.0000249130.63615.cc","volume":"67","author":"C Ballard","year":"2006","unstructured":"Ballard C, Ziabreva I, Perry R, Larsen JP, O\u2019Brien J, McKeith I, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology. 2006;67(11):1931\u20134. \n                    https:\/\/doi.org\/10.1212\/01.wnl.0000249130.63615.cc\n                    \n                  .","journal-title":"Neurology."},{"issue":"10004","key":"685_CR25","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/s0140-6736(15)00463-8","volume":"386","author":"JT O\u2019Brien","year":"2015","unstructured":"O\u2019Brien JT, Thomas A. Vascular dementia. Lancet (London, England). 2015;386(10004):1698\u2013706. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(15)00463-8\n                    \n                  .","journal-title":"Lancet (London, England)."},{"issue":"5","key":"685_CR26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/0891988716654987","volume":"29","author":"A Khan","year":"2016","unstructured":"Khan A, Kalaria RN, Corbett A, Ballard C. Update on vascular dementia. J Geriatr Psychiatry Neurol. 2016;29(5):281\u2013301. \n                    https:\/\/doi.org\/10.1177\/0891988716654987\n                    \n                  .","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"12","key":"685_CR27","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.neurobiolaging.2005.10.004","volume":"27","author":"GC Roman","year":"2006","unstructured":"Roman GC, Kalaria RN. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging. 2006;27(12):1769\u201385. \n                    https:\/\/doi.org\/10.1016\/j.neurobiolaging.2005.10.004\n                    \n                  .","journal-title":"Neurobiol Aging"},{"issue":"1","key":"685_CR28","doi-asserted-by":"publisher","first-page":"S257","DOI":"10.1111\/j.1440-1681.1995.tb02906.x","volume":"22","author":"H Saito","year":"1995","unstructured":"Saito H, Togashi H, Yoshioka M, Nakamura N, Minami M, Parvez H. Animal models of vascular dementia with emphasis on stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl. 1995;22(1):S257\u20139.","journal-title":"Clin Exp Pharmacol Physiol Suppl"},{"issue":"3\u20134","key":"685_CR29","first-page":"163","volume":"5","author":"CG Gottfries","year":"1994","unstructured":"Gottfries CG, Blennow K, Karlsson I, Wallin A. The neurochemistry of vascular dementia. Dementia (Basel, Switzerland). 1994;5(3\u20134):163\u20137.","journal-title":"Dementia (Basel, Switzerland)."},{"issue":"10","key":"685_CR30","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/bf01271206","volume":"103","author":"H Tohgi","year":"1996","unstructured":"Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm (Vienna, Austria : 1996). 1996;103(10):1211\u201320. \n                    https:\/\/doi.org\/10.1007\/bf01271206\n                    \n                  .","journal-title":"J Neural Transm (Vienna, Austria : 1996)"},{"issue":"1","key":"685_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1212\/01.wnl.0000148591.63727.80","volume":"64","author":"E Perry","year":"2005","unstructured":"Perry E, Ziabreva I, Perry R, Aarsland D, Ballard C. Absence of cholinergic deficits in \u201cpure\u201d vascular dementia. Neurology. 2005;64(1):132\u20133. \n                    https:\/\/doi.org\/10.1212\/01.wnl.0000148591.63727.80\n                    \n                  .","journal-title":"Neurology."},{"issue":"3","key":"685_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000239235","volume":"28","author":"SI Sharp","year":"2009","unstructured":"Sharp SI, Francis PT, Elliott MS, Kalaria RN, Bajic N, Hortobagyi T, et al. Choline acetyltransferase activity in vascular dementia and stroke. Dement Geriatr Cogn Disord. 2009;28(3):233\u20138. \n                    https:\/\/doi.org\/10.1159\/000239235\n                    \n                  .","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"685_CR33","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1161\/01.str.0000251787.90695.05","volume":"38","author":"JS Keverne","year":"2007","unstructured":"Keverne JS, Low WC, Ziabreva I, Court JA, Oakley AE, Kalaria RN. Cholinergic neuronal deficits in CADASIL. Stroke. 2007;38(1):188\u201391. \n                    https:\/\/doi.org\/10.1161\/01.str.0000251787.90695.05\n                    \n                  .","journal-title":"Stroke"},{"issue":"7","key":"685_CR34","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1212\/01.WNL.0000055927.22611.EB","volume":"60","author":"M Mesulam","year":"2003","unstructured":"Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infarct state: observations on CADASIL. Neurology. 2003;60(7):1183\u20135.","journal-title":"Neurology."},{"key":"685_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2017.00047","author":"Q Liu","year":"2017","unstructured":"Liu Q, Zhu Z, Teipel SJ, Yang J, Xing Y, Tang Y, et al. White matter damage in the cholinergic system contributes to cognitive impairment in subcortical vascular cognitive impairment, no dementia. Front Aging Neurosci. 2017. \n                    https:\/\/doi.org\/10.3389\/fnagi.2017.00047\n                    \n                  .","journal-title":"Front Aging Neurosci."},{"issue":"1","key":"685_CR36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1590\/S1980-57642008DN10100002","volume":"1","author":"E Engelhardt","year":"2007","unstructured":"Engelhardt E, Moreira DM, Laks J. Vascular dementia and the cholinergic pathways. Dement Neuropsychol. 2007;1(1):2\u20139. \n                    https:\/\/doi.org\/10.1590\/S1980-57642008DN10100002\n                    \n                  .","journal-title":"Dement Neuropsychol"},{"issue":"7","key":"685_CR37","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/aps.2009.82","volume":"30","author":"J Wang","year":"2009","unstructured":"Wang J, Zhang HY, Tang XC. Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment. Acta Pharmacol Sin. 2009;30(7):879\u201388. \n                    https:\/\/doi.org\/10.1038\/aps.2009.82\n                    \n                  .","journal-title":"Acta Pharmacol Sin"},{"issue":"14","key":"685_CR38","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2165\/00002512-200421140-00003","volume":"21","author":"R Moretti","year":"2004","unstructured":"Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21(14):931\u20137. \n                    https:\/\/doi.org\/10.2165\/00002512-200421140-00003\n                    \n                  .","journal-title":"Drugs Aging"},{"issue":"1","key":"685_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/2045125317739818","volume":"8","author":"JJ Young","year":"2018","unstructured":"Young JJ, Lavakumar M, Tampi D, Balachandran S, Tampi RR. Frontotemporal dementia: latest evidence and clinical implications. Ther Adv Psychopharmacol. 2018;8(1):33\u201348. \n                    https:\/\/doi.org\/10.1177\/2045125317739818\n                    \n                  .","journal-title":"Ther Adv Psychopharmacol"},{"issue":"10004","key":"685_CR40","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/s0140-6736(15)00461-4","volume":"386","author":"J Bang","year":"2015","unstructured":"Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet (Lond, Engl). 2015;386(10004):1672\u201382. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(15)00461-4\n                    \n                  .","journal-title":"Lancet (Lond, Engl)."},{"issue":"1","key":"685_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1212\/01.wnl.0000191304.55196.4d","volume":"66","author":"ED Huey","year":"2006","unstructured":"Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66(1):17\u201322. \n                    https:\/\/doi.org\/10.1212\/01.wnl.0000191304.55196.4d\n                    \n                  .","journal-title":"Neurology."},{"issue":"5","key":"685_CR42","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/brain\/awx327","volume":"141","author":"AG Murley","year":"2018","unstructured":"Murley AG, Rowe JB. Neurotransmitter deficits from frontotemporal lobar degeneration. Brain J Neurol. 2018;141(5):1263\u201385. \n                    https:\/\/doi.org\/10.1093\/brain\/awx327\n                    \n                  .","journal-title":"Brain J Neurol"},{"issue":"4","key":"685_CR43","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bcp.2015.07.016","volume":"97","author":"SS Minami","year":"2015","unstructured":"Minami SS, Shen V, Le D, Krabbe G, Asgarov R, Perez-Celajes L, et al. Reducing inflammation and rescuing FTD-related behavioral deficits in progranulin-deficient mice with \u03b17 nicotinic acetylcholine receptor agonists. Biochem Pharmacol. 2015;97(4):454\u201362. \n                    https:\/\/doi.org\/10.1016\/j.bcp.2015.07.016\n                    \n                  .","journal-title":"Biochem Pharmacol"},{"issue":"Suppl 1","key":"685_CR44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000074681","volume":"17","author":"KR Edwards","year":"2004","unstructured":"Edwards KR, Hershey L, Wray L, Bednarczyk EM, Lichter D, Farlow M, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriatr Cogn Disord. 2004;17(Suppl 1):40\u20138. \n                    https:\/\/doi.org\/10.1159\/000074681\n                    \n                  .","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"6","key":"685_CR45","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000101512","volume":"23","author":"K Edwards","year":"2007","unstructured":"Edwards K, Royall D, Hershey L, Lichter D, Hake A, Farlow M, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord. 2007;23(6):401\u20135. \n                    https:\/\/doi.org\/10.1159\/000101512\n                    \n                  .","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"9247","key":"685_CR46","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","volume":"356","author":"I McKeith","year":"2000","unstructured":"McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet (Lond, Engl). 2000;356(9247):2031\u20136. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(00)03399-7\n                    \n                  .","journal-title":"Lancet (Lond, Engl)."},{"issue":"2","key":"685_CR47","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1017\/S104161020100758X","volume":"13","author":"J Grace","year":"2001","unstructured":"Grace J, Daniel S, Stevens T, Shankar KK, Walker Z, Byrne EJ, et al. Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr. 2001;13(2):199\u2013205.","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"685_CR48","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1017\/S1041610201007670","volume":"13","author":"LE Maclean","year":"2001","unstructured":"Maclean LE, Collins CC, Byrne EJ. Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep. Int Psychogeriatr. 2001;13(3):277\u201388.","journal-title":"Int Psychogeriatr"},{"issue":"11","key":"685_CR49","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/1099-1166(200011)15:11<1028::AID-GPS227>3.0.CO;2-E","volume":"15","author":"JB Grace","year":"2000","unstructured":"Grace JB, Walker MP, McKeith IG. A comparison of sleep profiles in patients with dementia with lewy bodies and Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2000;15(11):1028\u201333.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"1","key":"685_CR50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1533317506297517","volume":"22","author":"L Rozzini","year":"2007","unstructured":"Rozzini L, Chilovi BV, Bertoletti E, Conti M, Delrio I, Trabucchi M, et al. Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer\u2019s disease: a case control study. Am J Alzheimer\u2019s Dis Other Dement. 2007;22(1):42\u20137. \n                    https:\/\/doi.org\/10.1177\/1533317506297517\n                    \n                  .","journal-title":"Am J Alzheimer\u2019s Dis Other Dement"},{"issue":"1","key":"685_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/ana.23557","volume":"72","author":"E Mori","year":"2012","unstructured":"Mori E, Ikeda M, Kosaka K, Donepezil DLBSI. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72(1):41\u201352. \n                    https:\/\/doi.org\/10.1002\/ana.23557\n                    \n                  .","journal-title":"Ann Neurol."},{"issue":"3\u20134","key":"685_CR52","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000351672","volume":"36","author":"M Ikeda","year":"2013","unstructured":"Ikeda M, Mori E, Kosaka K, Iseki E, Hashimoto M, Matsukawa N, et al. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study. Dement Geriatr Cogn Disord. 2013;36(3\u20134):229\u201341. \n                    https:\/\/doi.org\/10.1159\/000351672\n                    \n                  .","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"685_CR53","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13195-014-0083-0","volume":"7","author":"M Ikeda","year":"2015","unstructured":"Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther. 2015;7(1):4. \n                    https:\/\/doi.org\/10.1186\/s13195-014-0083-0\n                    \n                  .","journal-title":"Alzheimers Res Ther."},{"issue":"1","key":"685_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13195-014-0081-2","volume":"7","author":"E Mori","year":"2015","unstructured":"Mori E, Ikeda M, Nagai R, Matsuo K, Nakagawa M, Kosaka K. Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial. Alzheimers Res Ther. 2015;7(1):5. \n                    https:\/\/doi.org\/10.1186\/s13195-014-0081-2\n                    \n                  .","journal-title":"Alzheimers Res Ther."},{"key":"685_CR55","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jns.2016.05.001","volume":"366","author":"E Mori","year":"2016","unstructured":"Mori E, Ikeda M, Nakai K, Miyagishi H, Nakagawa M, Kosaka K. Increased plasma donepezil concentration improves cognitive function in patients with dementia with Lewy bodies: an exploratory pharmacokinetic\/pharmacodynamic analysis in a phase 3 randomized controlled trial. J Neurol Sci. 2016;366:184\u201390. \n                    https:\/\/doi.org\/10.1016\/j.jns.2016.05.001\n                    \n                  .","journal-title":"J Neurol Sci"},{"issue":"1\u20132","key":"685_CR56","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000447586","volume":"42","author":"E Mori","year":"2016","unstructured":"Mori E, Ikeda M, Nakagawa M, Miyagishi H, Kosaka K. Pretreatment cognitive profile likely to benefit from donepezil treatment in dementia with lewy bodies: pooled analyses of two randomized controlled trials. Dement Geriatr Cogn Disord. 2016;42(1\u20132):58\u201368. \n                    https:\/\/doi.org\/10.1159\/000447586\n                    \n                  .","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"9","key":"685_CR57","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/1099-1166(200009)15:9<794::AID-GPS178>3.0.CO;2-1","volume":"15","author":"W Samuel","year":"2000","unstructured":"Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry. 2000;15(9):794\u2013802.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"8","key":"685_CR58","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/gps.1547","volume":"21","author":"S Pakrasi","year":"2006","unstructured":"Pakrasi S, Thomas A, Mosimann UP, Cousins DA, Lett D, Burn DJ, et al. Cholinesterase inhibitors in advanced Dementia with Lewy bodies: increase or stop? Int J Geriatr Psychiatry. 2006;21(8):719\u201321. \n                    https:\/\/doi.org\/10.1002\/gps.1547\n                    \n                  .","journal-title":"Int J Geriatr Psychiatry."},{"issue":"2","key":"685_CR59","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1440-1819.2006.01485.x","volume":"60","author":"S Mori","year":"2006","unstructured":"Mori S, Mori E, Iseki E, Kosaka K. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study. Psychiatry Clin Neurosci. 2006;60(2):190\u20135. \n                    https:\/\/doi.org\/10.1111\/j.1440-1819.2006.01485.x\n                    \n                  .","journal-title":"Psychiatry Clin Neurosci"},{"issue":"3","key":"685_CR60","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000098335","volume":"23","author":"E Rowan","year":"2007","unstructured":"Rowan E, McKeith IG, Saxby BK, O\u2019Brien JT, Burn D, Mosimann U, et al. Effects of donepezil on central processing speed and attentional measures in Parkinson\u2019s disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2007;23(3):161\u20137. \n                    https:\/\/doi.org\/10.1159\/000098335\n                    \n                  .","journal-title":"Dement Geriatr Cogn Disord"},{"key":"685_CR61","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.psychres.2017.02.039","volume":"251","author":"H Kazui","year":"2017","unstructured":"Kazui H, Adachi H, Kanemoto H, Yoshiyama K, Wada T, Tokumasu Nomura K, et al. Effects of donepezil on sleep disturbances in patients with dementia with Lewy bodies: an open-label study with actigraphy. Psychiatry Res. 2017;251:312\u20138. \n                    https:\/\/doi.org\/10.1016\/j.psychres.2017.02.039\n                    \n                  .","journal-title":"Psychiatry Res"},{"issue":"4","key":"685_CR62","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1479-8301.2012.00411.x","volume":"12","author":"A Ozaki","year":"2012","unstructured":"Ozaki A, Nishida M, Koyama K, Ishikawa K, Nishikawa T. Donepezil-induced sleep spindle in a patient with dementia with Lewy bodies: a case report. Psychogeriatrics. 2012;12(4):255\u20138. \n                    https:\/\/doi.org\/10.1111\/j.1479-8301.2012.00411.x\n                    \n                  .","journal-title":"Psychogeriatrics."},{"issue":"3","key":"685_CR63","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1440-1819.2010.02088.x","volume":"64","author":"Y Fujita","year":"2010","unstructured":"Fujita Y, Takebayashi M. Efficacy of low-dose donepezil for visual hallucinations in a patient with dementia with Lewy bodies. Psychiatry Clin Neurosci. 2010;64(3):336. \n                    https:\/\/doi.org\/10.1111\/j.1440-1819.2010.02088.x\n                    \n                  .","journal-title":"Psychiatry Clin Neurosci"},{"issue":"6","key":"685_CR64","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1159\/000322121","volume":"64","author":"M Satoh","year":"2010","unstructured":"Satoh M, Ishikawa H, Meguro K, Kasuya M, Ishii H, Yamaguchi S. Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project. Eur Neurol. 2010;64(6):337\u201344. \n                    https:\/\/doi.org\/10.1159\/000322121\n                    \n                  .","journal-title":"Eur Neurol"},{"issue":"2","key":"685_CR65","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/psyg.12089","volume":"15","author":"K Ukai","year":"2015","unstructured":"Ukai K, Fujishiro H, Iritani S, Ozaki N. Long-term efficacy of donepezil for relapse of visual hallucinations in patients with dementia with Lewy bodies. Psychogeriatrics. 2015;15(2):133\u20137. \n                    https:\/\/doi.org\/10.1111\/psyg.12089\n                    \n                  .","journal-title":"Psychogeriatrics."},{"issue":"24","key":"685_CR66","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa041470","volume":"351","author":"M Emre","year":"2004","unstructured":"Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson\u2019s disease. N Engl J Med. 2004;351(24):2509\u201318. \n                    https:\/\/doi.org\/10.1056\/NEJMoa041470\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"4","key":"685_CR67","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/mds.20700","volume":"21","author":"W Poewe","year":"2006","unstructured":"Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson\u2019s disease: an active treatment extension study. Mov Disord. 2006;21(4):456\u201361. \n                    https:\/\/doi.org\/10.1002\/mds.20700\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"10","key":"685_CR68","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/gps.949","volume":"18","author":"D Aarsland","year":"2003","unstructured":"Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson\u2019s disease with dementia. Int J Geriatr Psychiatry. 2003;18(10):937\u201341. \n                    https:\/\/doi.org\/10.1002\/gps.949\n                    \n                  .","journal-title":"Int J Geriatr Psychiatry."},{"issue":"9","key":"685_CR69","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s11055-008-9077-3","volume":"38","author":"IV Litvinenko","year":"2008","unstructured":"Litvinenko IV, Odinak MM, Mogil\u2019naya VI, Emelin AY. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson\u2019s disease (an open controlled trial). Neurosci Behav Physiol. 2008;38(9):937\u201345. \n                    https:\/\/doi.org\/10.1007\/s11055-008-9077-3\n                    \n                  .","journal-title":"Neurosci Behav Physiol"},{"issue":"3","key":"685_CR70","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000338774","volume":"68","author":"K Hiraoka","year":"2012","unstructured":"Hiraoka K, Okamura N, Funaki Y, Hayashi A, Tashiro M, Hisanaga K, et al. Cholinergic deficit and response to donepezil therapy in Parkinson\u2019s disease with dementia. Eur Neurol. 2012;68(3):137\u201343. \n                    https:\/\/doi.org\/10.1159\/000338774\n                    \n                  .","journal-title":"Eur Neurol"},{"issue":"11","key":"685_CR71","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s007020100008","volume":"108","author":"EA Werber","year":"2001","unstructured":"Werber EA, Rabey JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson\u2019s disease and dementia. J Neural Transm (Vienna, Austria: 1996). 2001;108(11):1319\u201325. \n                    https:\/\/doi.org\/10.1007\/s007020100008\n                    \n                  .","journal-title":"J Neural Transm (Vienna, Austria: 1996)"},{"issue":"10","key":"685_CR72","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/gps.1381","volume":"20","author":"AJ Thomas","year":"2005","unstructured":"Thomas AJ, Burn DJ, Rowan EN, Littlewood E, Newby J, Cousins D, et al. A comparison of the efficacy of donepezil in Parkinson\u2019s disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2005;20(10):938\u201344. \n                    https:\/\/doi.org\/10.1002\/gps.1381\n                    \n                  .","journal-title":"Int J Geriatr Psychiatry."},{"issue":"1","key":"685_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/gps.993","volume":"19","author":"I Leroi","year":"2004","unstructured":"Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson\u2019s disease. Int J Geriatr Psychiatry. 2004;19(1):1\u20138. \n                    https:\/\/doi.org\/10.1002\/gps.993\n                    \n                  .","journal-title":"Int J Geriatr Psychiatry."},{"issue":"7","key":"685_CR74","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1136\/jnnp.2004.050682","volume":"76","author":"B Ravina","year":"2005","unstructured":"Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, et al. Donepezil for dementia in Parkinson\u2019s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76(7):934\u20139. \n                    https:\/\/doi.org\/10.1136\/jnnp.2004.050682\n                    \n                  .","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"685_CR75","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/mds.25098","volume":"27","author":"B Dubois","year":"2012","unstructured":"Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, et al. Donepezil in Parkinson\u2019s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012;27(10):1230\u20138. \n                    https:\/\/doi.org\/10.1002\/mds.25098\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"4","key":"685_CR76","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/01.WNL.0000078943.50032.FC","volume":"61","author":"D Wilkinson","year":"2003","unstructured":"Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003;61(4):479\u201386.","journal-title":"Neurology."},{"issue":"10","key":"685_CR77","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1161\/01.STR.0000091396.95360.E1","volume":"34","author":"S Black","year":"2003","unstructured":"Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34(10):2323\u201330. \n                    https:\/\/doi.org\/10.1161\/01.STR.0000091396.95360.E1\n                    \n                  .","journal-title":"Stroke"},{"issue":"3","key":"685_CR78","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/gps.2340","volume":"25","author":"D Wilkinson","year":"2010","unstructured":"Wilkinson D, Roman G, Salloway S, Hecker J, Boundy K, Kumar D, et al. The long-term efficacy and tolerability of donepezil in patients with vascular dementia. Int J Geriatr Psychiatry. 2010;25(3):305\u201313. \n                    https:\/\/doi.org\/10.1002\/gps.2340\n                    \n                  .","journal-title":"Int J Geriatr Psychiatry."},{"issue":"6","key":"685_CR79","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1161\/STROKEAHA.109.570077","volume":"41","author":"GC Roman","year":"2010","unstructured":"Roman GC, Salloway S, Black SE, Royall DR, Decarli C, Weiner MW, et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke. 2010;41(6):1213\u201321. \n                    https:\/\/doi.org\/10.1161\/STROKEAHA.109.570077\n                    \n                  .","journal-title":"Stroke"},{"issue":"4","key":"685_CR80","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/1533317509334960","volume":"24","author":"JC Kwon","year":"2009","unstructured":"Kwon JC, Kim EG, Kim JW, Kwon OD, Yoo BG, Yi HA, et al. A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia. Am J Alzheimer\u2019s Dis Other Dement. 2009;24(4):293\u2013301. \n                    https:\/\/doi.org\/10.1177\/1533317509334960\n                    \n                  .","journal-title":"Am J Alzheimer\u2019s Dis Other Dement"},{"issue":"9314","key":"685_CR81","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","volume":"359","author":"T Erkinjuntti","year":"2002","unstructured":"Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: a randomised trial. Lancet (Lond, Engl). 2002;359(9314):1283\u201390. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(02)08267-3\n                    \n                  .","journal-title":"Lancet (Lond, Engl)."},{"issue":"6","key":"685_CR82","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0149-2918(03)80168-6","volume":"25","author":"T Erkinjuntti","year":"2003","unstructured":"Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV, et al. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther. 2003;25(6):1765\u201382.","journal-title":"Clin Ther"},{"issue":"5","key":"685_CR83","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/01.wnl.0000266625.31615.f6","volume":"69","author":"AP Auchus","year":"2007","unstructured":"Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C, et al. Galantamine treatment of vascular dementia: a randomized trial. Neurology. 2007;69(5):448\u201358. \n                    https:\/\/doi.org\/10.1212\/01.wnl.0000266625.31615.f6\n                    \n                  .","journal-title":"Neurology."},{"key":"685_CR84","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0022-510X(02)00280-0","volume":"203\u2013204","author":"R Moretti","year":"2002","unstructured":"Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci. 2002;203\u2013204:141\u20136.","journal-title":"J Neurol Sci"},{"issue":"6","key":"685_CR85","first-page":"943","volume":"3","author":"V Mok","year":"2007","unstructured":"Mok V, Wong A, Ho S, Leung T, Lam WW, Wong KS. Rivastigmine in Chinese patients with subcortical vascular dementia. Neuropsychiatr Dis Treat. 2007;3(6):943\u20138.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"5","key":"685_CR86","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/153331750301800508","volume":"18","author":"R Moretti","year":"2003","unstructured":"Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimer\u2019s Dis Other Dement. 2003;18(5):265\u201372. \n                    https:\/\/doi.org\/10.1177\/153331750301800508\n                    \n                  .","journal-title":"Am J Alzheimer\u2019s Dis Other Dement"},{"issue":"2","key":"685_CR87","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/1533317507312558","volume":"23","author":"R Moretti","year":"2008","unstructured":"Moretti R, Torre P, Antonello RM, Cazzato G, Pizzolato G. Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia. Am J Alzheimer\u2019s Dis Other Dement. 2008;23(2):167\u201376. \n                    https:\/\/doi.org\/10.1177\/1533317507312558\n                    \n                  .","journal-title":"Am J Alzheimer\u2019s Dis Other Dement"},{"issue":"9","key":"685_CR88","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1185\/03007990802328142","volume":"24","author":"C Ballard","year":"2008","unstructured":"Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten EC, et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin. 2008;24(9):2561\u201374. \n                    https:\/\/doi.org\/10.1185\/03007990802328142\n                    \n                  .","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"685_CR89","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000113034","volume":"25","author":"A Kertesz","year":"2008","unstructured":"Kertesz A, Morlog D, Light M, Blair M, Davidson W, Jesso S, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25(2):178\u201385. \n                    https:\/\/doi.org\/10.1159\/000113034\n                    \n                  .","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"685_CR90","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/01.JGP.0000231744.69631.33","volume":"15","author":"MF Mendez","year":"2007","unstructured":"Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15(1):84\u20137. \n                    https:\/\/doi.org\/10.1097\/01.JGP.0000231744.69631.33\n                    \n                  .","journal-title":"Am J Geriatr Psychiatry."},{"issue":"3","key":"685_CR91","doi-asserted-by":"publisher","first-page":"E25","DOI":"10.1176\/appi.neuropsych.12060158","volume":"25","author":"DB Arciniegas","year":"2013","unstructured":"Arciniegas DB, Anderson CA. Donepezil-induced confusional state in a patient with autopsy-proven behavioral-variant frontotemporal dementia. J Neuropsychiatry Clin Neurosci. 2013;25(3):E25\u20136. \n                    https:\/\/doi.org\/10.1176\/appi.neuropsych.12060158\n                    \n                  .","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"685_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd003735","author":"R Katzenschlager","year":"2003","unstructured":"Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson\u2019s disease. Cochrane Database Syst Rev. 2003. \n                    https:\/\/doi.org\/10.1002\/14651858.cd003735\n                    \n                  .","journal-title":"Cochrane Database Syst Rev."},{"issue":"3\u20134","key":"685_CR93","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000433524","volume":"40","author":"E Mori","year":"2015","unstructured":"Mori E, Ikeda M, Nakagawa M, Miyagishi H, Yamaguchi H, Kosaka K. Effects of donepezil on extrapyramidal symptoms in patients with dementia with lewy bodies: a secondary pooled analysis of two randomized-controlled and two open-label long-term extension studies. Dement Geriatr Cogn Disord. 2015;40(3\u20134):186\u201398. \n                    https:\/\/doi.org\/10.1159\/000433524\n                    \n                  .","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"685_CR94","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2165\/00002018-200831010-00007","volume":"31","author":"W Oertel","year":"2008","unstructured":"Oertel W, Poewe W, Wolters E, De Deyn PP, Emre M, Kirsch C, et al. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson\u2019s disease dementia: a retrospective analysis of a double-blind trial and an open-label extension. Drug Saf. 2008;31(1):79\u201394. \n                    https:\/\/doi.org\/10.2165\/00002018-200831010-00007\n                    \n                  .","journal-title":"Drug Saf"},{"issue":"3","key":"685_CR95","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/2042098617750555","volume":"9","author":"R Khoury","year":"2018","unstructured":"Khoury R, Rajamanickam J, Grossberg GT. An update on the safety of current therapies for Alzheimer\u2019s disease: focus on rivastigmine. Ther Adv Drug Saf. 2018;9(3):171\u20138. \n                    https:\/\/doi.org\/10.1177\/2042098617750555\n                    \n                  .","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"685_CR96","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/WNF.0000000000000010","volume":"37","author":"M Emre","year":"2014","unstructured":"Emre M, Poewe W, De Deyn PP, Barone P, Kulisevsky J, Pourcher E, et al. Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study. Clin Neuropharmacol. 2014;37(1):9\u201316. \n                    https:\/\/doi.org\/10.1097\/WNF.0000000000000010\n                    \n                  .","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"685_CR97","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","volume":"86","author":"HF Wang","year":"2015","unstructured":"Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86(2):135\u201343. \n                    https:\/\/doi.org\/10.1136\/jnnp-2014-307659\n                    \n                  .","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"685_CR98","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3892\/etm.2018.7129","volume":"17","author":"Y-H Meng","year":"2019","unstructured":"Meng Y-H, Wang P-P, Song Y-X, Wang J-H. Cholinesterase inhibitors and memantine for Parkinson\u2019s disease dementia and Lewy body dementia: a meta-analysis. Exp Ther Med. 2019;17(3):1611\u201324. \n                    https:\/\/doi.org\/10.3892\/etm.2018.7129\n                    \n                  .","journal-title":"Exp Ther Med"},{"issue":"6","key":"685_CR99","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/1533317511424892","volume":"26","author":"D Weintraub","year":"2011","unstructured":"Weintraub D, Somogyi M, Meng X. Rivastigmine in Alzheimer\u2019s disease and Parkinson\u2019s disease dementia: an ADAS-cog factor analysis. Am J Alzheimer\u2019s Dis other Dement. 2011;26(6):443\u20139. \n                    https:\/\/doi.org\/10.1177\/1533317511424892\n                    \n                  .","journal-title":"Am J Alzheimer\u2019s Dis other Dement"},{"issue":"9","key":"685_CR100","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","volume":"6","author":"H Kavirajan","year":"2007","unstructured":"Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6(9):782\u201392. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(07)70195-3\n                    \n                  .","journal-title":"Lancet Neurol."},{"issue":"1","key":"685_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13670-018-0234-4","volume":"7","author":"NI Bohnen","year":"2018","unstructured":"Bohnen NI, Grothe MJ, Ray NJ, Muller M, Teipel SJ. Recent advances in cholinergic imaging and cognitive decline-Revisiting the cholinergic hypothesis of dementia. Curr Geriatr Rep. 2018;7(1):1\u201311. \n                    https:\/\/doi.org\/10.1007\/s13670-018-0234-4\n                    \n                  .","journal-title":"Curr Geriatr Rep"},{"issue":"2","key":"685_CR102","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijpsycho.2009.01.011","volume":"73","author":"DF Fotiou","year":"2009","unstructured":"Fotiou DF, Stergiou V, Tsiptsios D, Lithari C, Nakou M, Karlovasitou A. Cholinergic deficiency in Alzheimer\u2019s and Parkinson\u2019s disease: evaluation with pupillometry. Int J Psychophysiol. 2009;73(2):143\u20139. \n                    https:\/\/doi.org\/10.1016\/j.ijpsycho.2009.01.011\n                    \n                  .","journal-title":"Int J Psychophysiol"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00685-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-019-00685-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00685-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T23:32:02Z","timestamp":1592004722000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-019-00685-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,14]]},"references-count":102,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["685"],"URL":"https:\/\/doi.org\/10.1007\/s40266-019-00685-6","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,14]]},"assertion":[{"value":"14 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was not funded.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Authors PN, RK, and SJ declare that they have no conflict of interest. Author GG is a consultant for Acadia, Alkahest, Allergen, Avanir, Axovant, Bioxcel, GE, Genentech, Lundbeck, Novartis, Otsuka, Roche, and Takeda; received research support from Janssen, NIA, and Roche; is on the safety monitoring committee for EryDel, Merck and Newron; and is on the Speaker\u2019s Bureau for Acadia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}